Prevention of kidney cell damage in hyperglycaemia condition by adiponectin
Sajad Esmaeili1, Maryam Motamedrad2, Mina Hemmati3
1Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.
Abstract:
Adiponectin (APN) is an adipocytokine, secreted from adipose tissue and has anti-inflammatory, anti-ageing, and antidiabetic properties. Hyperglycaemia can damage the renal cells, and mammalian target of rapamycin (mTOR), along with Sirtuin 1 (SIRT1), have an important role in kidney cell response to hyperglycaemia. Therefore, understanding the relationship between adiponectin, mTOR, and SIRT1 proteins is beneficial for deciphering the mechanism of adiponectin function. In this study, Human Embryonic Kidney-293 (HEK-293) cells were cultured under normal and high-glucose condition, with and without APN (1, 10, and 100 ng/mL) for 48 hours. mTOR protein expression was evaluated by western blot analysis, and SIRT1 protein was assessed using ELISA method. To evaluate hyperglycaemia-mediated cytotoxicity, cell viability was determined using MTT assay. Data showed that APN in high dose (100 ng/mL) significantly reduced the expression of mTOR and p-mTOR, increased SIRT1 protein, and also improved cell viability compared with the control high glucose (p ≤ 0.05). According to this results, APN can be useful in preventing renal cell damage, by affecting on the expression of mTOR and SIRT1 proteins, as well as increasing the survival of kidney cells in hyperglycaemia conditions. SIGNIFICANCE OF THE STUDY: Adiponectin triggered mTOR/p-mTOR/SIRT1 pathway and decreased cell death in human kidney cells. Our findings provide preliminary experimental data that support further studies on the potential therapeutic role of adiponectin in diabetes and diabetic-induced metabolic complications.
Insights
Adiponectin (APN) protects kidney cells from high glucose damage by reducing mTOR and increasing SIRT1. This suggests APN’s therapeutic potential for diabetic kidney complications.
Area of Science:
- Biochemistry
- Cell Biology
- Endocrinology
Background:
- Adiponectin (APN) is an adipokine with anti-inflammatory and antidiabetic effects.
- Hyperglycemia-induced renal cell damage involves mammalian target of rapamycin (mTOR) and Sirtuin 1 (SIRT1).
- Understanding the APN, mTOR, and SIRT1 interplay is crucial for elucidating APN's kidney-protective mechanisms.
Purpose of the Study:
- To investigate the effect of adiponectin on mTOR and SIRT1 expression in human kidney cells under high-glucose conditions.
- To evaluate adiponectin's role in mitigating hyperglycemia-induced cytotoxicity in renal cells.
Main Methods:
- Human Embryonic Kidney-293 (HEK-293) cells were cultured with varying concentrations of APN under normal and high-glucose conditions.
- Western blot analysis was used to assess mTOR protein expression.
- ELISA and MTT assays were employed to measure SIRT1 protein levels and cell viability, respectively.
Main Results:
- High-dose adiponectin (100 ng/mL) significantly reduced mTOR and p-mTOR expression.
- Adiponectin treatment increased SIRT1 protein levels in high-glucose conditions.
- APN significantly improved cell viability compared to untreated high-glucose controls.
Conclusions:
- Adiponectin modulates the mTOR/p-mTOR/SIRT1 pathway in human kidney cells.
- APN demonstrates potential in preventing renal cell damage and reducing cell death under hyperglycemic conditions.
- These findings support further research into adiponectin's therapeutic applications for diabetes and related metabolic complications.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Structure
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Cancer Prevention
Some...
Prevention of Further Absorption of Poison


